Ireland
--:--IST
Latest
Clinical Trials in Israel / NCT07484815
Recruiting Not applicable

Virtual Reality Intervention to Reduce Pain in Women Undergoing Elective Oocyte Cryopreservation

NCT07484815 · tracked via the Priya Life Science Israel tracker
Phase
Not applicable
Started
2024-11-05
Last updated
2026-03-20

Condition(s) studied

Procedure-Related PainAcute Pain

Investigational drug(s) / intervention(s)

Virtual reality relaxation interventionStandard Care Control

Virtual reality relaxation intervention: Participants are exposed to relaxing virtual reality nature scenery videos using a VR headset for approximately 20 minutes prior to oocyte retrieval, in addition to routine care.

Standard Care Control: Participants receive routine care prior to oocyte retrieval without exposure to virtual reality.

Study summary

This randomized controlled study evaluates whether exposure to relaxing virtual reality (VR) scenery prior to oocyte retrieval can reduce pain in women undergoing elective oocyte cryopreservation.

Many women experience discomfort before and after oocyte retrieval. Virtual reality has been shown to reduce pain in various medical settings by providing distraction and relaxation.

In this study, participants are randomly assigned to receive either routine care alone or routine care combined with a VR-based relaxation intervention while waiting for the procedure.

Pain is assessed using validated questionnaires and standardized scales before and after oocyte retrieval.

The results of this study may help determine whether VR can serve as a simple, safe, and non-pharmacological method to improve patient comfort during elective egg freezing.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Women undergoing elective oocyte retrieval for fertility preservation. * Age 18-45 years. * Ability to provide informed consent. Exclusion Criteria: * Use of pain relief, anti-anxiety, or antidepressant medications prior to the intervention. * Any condition for which VR use is not recommended, including: * History of seizures * Sensitivity to flashing light or motion * Migraine headaches * Predisposition to nausea or dizziness (e.g., vertigo) * Any injury to the eyes, face, or neck limiting use of the VR device, including blindness.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hadassah Medical Organization Jerusalem Israel Recruiting

More Hadassah Medical Organization trials in Israel

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07484815 on ClinicalTrials.gov ↗ ← All trials in Israel